BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A. Blood Targets of Adjuvant Drugs Against COVID19. J Blood Med 2020;11:237-41. [PMID: 32694923 DOI: 10.2147/JBM.S256121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Singla RK, He X, Chopra H, Tsagkaris C, Shen L, Kamal MA, Shen B. Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources. Front Pharmacol 2021;12:758159. [PMID: 34925017 DOI: 10.3389/fphar.2021.758159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
2 Di Micco P, Imbalzano E, Russo V, Attena E, Mandaliti V, Orlando L, Lombardi M, Di Micco G, Camporese G, Annunziata S, Piccinocchi G, Pacelli W, Del Guercio M. Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses 2021;13:2486. [PMID: 34960754 DOI: 10.3390/v13122486] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
3 Ma H, Lim XC, Yu Q, Li Y, Li Y, Jia W. Ratios between circulating myeloid cells and lymphocytes are associated with mortality in severe COVID-19 patients. Open Medicine 2021;16:351-60. [DOI: 10.1515/med-2021-0237] [Reference Citation Analysis]
4 Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A, Castaldo G, Agrusta F, Bellizzi A, Amitrano M, Iannuzzo M, Sacco C, Lodigiani C, Fontanella A, Di Micco P; FondenoxavidStudy Group. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. J Blood Med 2021;12:69-75. [PMID: 33603528 DOI: 10.2147/JBM.S285214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]